This is an author's reply letter responding to commentary on the MAGPIE trial — a randomised clinical trial of inhaled low-dose methoxyflurane (Penthrox®) vs. placebo for acute trauma-related pain in children and adolescents. The reply addresses the applicability of the minimum clinically important difference (MCID) from adult postoperative pain contexts to paediatric acute pain settings.
The authors note that the MCID in acute pain settings varies widely — absolute MCID ranges from 8 to 40 mm (VAS) and relative difference from 13% to 85% — highlighting that an adult postoperative MCID may not be appropriate for paediatric acute pain.
This is a short correspondence letter with no new primary data; it does not resolve the MCID debate for paediatric acute pain settings, and full text was not accessible for complete assessment.
When interpreting pain trial results in children, clinicians should be cautious about applying adult-derived MCID thresholds, as the paediatric acute pain MCID remains uncertain and context-dependent. The MAGPIE trial findings for methoxyflurane in paediatric trauma pain should be interpreted with this nuance in mind.
Explore related topics
